 IMV Inc. Nasdaq: IMV; TSX: IMV, a clinical-stage biopharmaceutical company pioneering a novel class of targeted cancer immunotherapies and vaccines against infectious diseases, today reported updated clinical response and translational data from DeCidE1, its Phase 2 study evaluating the safety and efficacy of DPX-Survivac with intermittent low-dose cyclophosphamide CPA in patients with recurrent, advanced platinum-sensitive and -resistant ovarian cancer. 